Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17805301 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Dentin R, et al. (2007) Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature 449, 366-9 17805301
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S358-p - QIK (mouse)
Orthologous residues
QIK (human): S358‑p, QIK (mouse): S358‑p, QIK (rat): S358‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
 Relevant cell lines - cell types - tissues:  293T (epithelial), hepatocyte-liver
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  human, mouse
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE Akt2 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt2 (mouse) phospho-motif antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
LY294002 inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced

S171-p - TORC2 (mouse)
Orthologous residues
TORC2 (human): S171‑p, TORC2 (mouse): S171‑p, TORC2 (rat): S171‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody
 Relevant cell lines - cell types - tissues:  293T (epithelial), hepatocyte-liver, HepG2 (hepatic)
 Cellular systems studied:  cell lines, primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE QIK (mouse) activation of upstream enzyme, siRNA inhibition of enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
meal feeding increase
fasting decrease
refeeding increase
insulin increase
forskolin, insulin inhibit treatment-induced increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited, intracellular localization, protein degradation
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
COP1 (mouse) Not reported co-immunoprecipitation
 Comments:  phosphorylation of this site stimulated by meal feeding or insulin alone leads to TORC2 cytoplasmic translocation and its ubiquitin-based degradation;

K628-ub - TORC2 (mouse)
Orthologous residues
TORC2 (human): K629‑ub, TORC2 (mouse): K628‑ub, TORC2 (rat): K627‑ub
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Relevant cell lines - cell types - tissues:  293T (epithelial)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  protein degradation


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.